Study of the Aliviado DSD Caregiving Mastery Program

Sponsor
NYU Langone Health (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05630014
Collaborator
National Institute on Aging (NIA) (NIH)
40
1
1
5.3
7.6

Study Details

Study Description

Brief Summary

Delirium superimposed on dementia (DSD) is an acute and serious condition that is common in persons living with dementia (PLWD). Involvement of family caregivers may aid prevention, early detection, and management of DSD. The purpose of the proposed study is two-fold. First, the investigators will develop a family-centered, mHealth-enhanced DSD caregiving mastery program ("Aliviado DSD Caregiving Mastery Program") through a 5-week co-design workshop with 8 family caregivers (Aim 1). The investigators will adapt/refine the existing clinician-centered DSD contents and an mHealth app from the evidence-based "Aliviado Dementia Care" program for use by family caregivers to support their day-to-day implementation of DSD detection, prevention, and management tasks in the community. Second, the investigators will pilot test the full Aliviado DSD Caregiving Mastery Program with 30 family caregivers of PLWD at high risk for delirium, assessing feasibility, acceptability, app usability, and preliminary program impact (Aim 2).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Aliviado DSD Caregiving Mastery Program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Development and Piloting of a Family-Centered, mHealth-Enhanced Intervention to Promote Caregiving Mastery in Detection, Prevention, and Management of Delirium Superimposed on Dementia
Anticipated Study Start Date :
Jan 20, 2023
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Family Caregivers of PLWD at High Risk for Delirium

Participants will complete the Aliviado DSD Caregiving Mastery Program. This involves a caregiver education/training period from Week 0 to Week 2, and an implementation period from Week 3 to Week 6.

Behavioral: Aliviado DSD Caregiving Mastery Program
Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.

Outcome Measures

Primary Outcome Measures

  1. Number of Participants who Complete the Study [Week 6]

    Measure of feasibility. Feasibility indicated by retention rate of 85%.

  2. Program Satisfaction Questionnaire Score [Week 6]

    Questionnaire comprises 13 Likert-type questions to assess program satisfaction and willingness to recommend the program. Includes one optional open-ended question to provide additional feedback.

  3. Number of Participants who Complete all Training Videos by Week 2 [Up to Week 2]

    Measure of acceptability.

  4. Number of Participants who Complete Weekly Delirium Screening at Least Twice by Week 6 [Up to Week 6]

    Measure of acceptability.

  5. Modified IBM Computer Usability Satisfaction Questionnaire Score [Week 6]

    Developed by the Aliviado team; consists of 24 Likert-type questions, plus 3 optional open-ended questions to provide additional feedback. Higher scores indicate greater usability.

Secondary Outcome Measures

  1. Change from Baseline in Caregiver Delirium Knowledge Questionnaire Score at Week 2 [Baseline, Week 2]

    19-item assessment of caregivers' delirium knowledge. Item response options include "yes," "no," and "I don't know." Correct responses receive a score of 1, incorrect responses receive a score of 0. The total score ranges from 0-19; higher scores indicate greater delirium knowledge.

  2. Change from Baseline in Caregiver Delirium Knowledge Questionnaire Score at Week 6 [Baseline, Week 6]

    19-item assessment of caregivers' delirium knowledge. Item response options include "yes," "no," and "I don't know." Correct responses receive a score of 1, incorrect responses receive a score of 0. The total score ranges from 0-19; higher scores indicate greater delirium knowledge.

  3. Change from Baseline in Modified Caregiver Strain Index Score at Week 6 [Baseline, Week 6]

    13-item assessment of strain related to care provision. Items are scored on a Likert scale from 0 (no) to 2 (Yes, on a regular basis). The total score is the sum of responses and ranges from 0 to 26; higher scores indicate greater strain.

  4. Change from Baseline in Center for Epidemiological Studies Depression Scale (CES-D) Score at Week 6 [Baseline, Week 6]

    20-item assessment of symptoms of depression over the past 7 days. The total score ranges from 0 to 60, with higher scores indicating the presence of more symptomatology.

  5. Change from Baseline in Short Form Zarit Burden Interview Score at Week 6 [Baseline, Week 6]

    12-item assessment of caregiver burden. Items are scored on a Likert scale from 0 (never) to 4 (nearly always). The total score is the sum of responses and ranges from 0 to 48. A score of 0-10 indicates no to mild burden; 10-20 indicates mild to moderate burden; and greater than 20 indicates high burden.

  6. Change from Baseline in DSD Caregiving Mastery Assessment Score at Week 2 [Baseline, Week 2]

    14-item DSD Competence Scale modified from Pearline's Competence Scale with additional items developed by the Aliviado team to assess confidence and completion of DSD prevention, detection, and management tasks. Higher scores indicate greater levels of mastery.

  7. Change from Baseline in DSD Caregiving Mastery Assessment Score at Week 6 [Baseline, Week 6]

    14-item DSD Competence Scale modified from Pearline's Competence Scale with additional items developed by the Aliviado team to assess confidence and completion of DSD prevention, detection, and management tasks. Higher scores indicate greater levels of mastery.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
To be eligible as a "dementia caregiver" in the co-design workshop, an individual must:
  • be at least 18 years old,

  • be English-speaking,

  • provide at least 8 hours of unpaid care weekly or live with a community-dwelling PLWD,

  • self-identify as unfamiliar with DSD,

  • have the capacity to consent, and

  • have Internet access

To be eligible as a "DSD caregiver" in the co-design workshop, an individual must:
  • be at least 18 years old,

  • be English-speaking,

  • be a current or past dementia caregiver with experience caring for a relative or friend during his/her DSD episode within the past 12 months,

  • have the capacity to consent, and

  • have Internet access.

To be eligible to participate in the feasibility trial, an individual must meet all of the following criteria:

  • Being 18 years old or older,

  • English-speaking,

  • Providing at least 8 hours of unpaid care per week to, or living with, a community dwelling PLWD whose Delirium Risk Assessment Score >=5,

  • Having the capacity to give informed consent, and

  • Having a smartphone with Internet access.

Exclusion Criteria:
  • Individuals who are blind or deaf will be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 NYU Langone Health New York New York United States 10010

Sponsors and Collaborators

  • NYU Langone Health
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Shih-Yin Lin, NYU Rory Meyers College of Nursing

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
NYU Langone Health
ClinicalTrials.gov Identifier:
NCT05630014
Other Study ID Numbers:
  • 22-01093
First Posted:
Nov 29, 2022
Last Update Posted:
Jan 6, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 6, 2023